Announced Tue, 21 Jul · 17:21 IST
Tatva Chintan Q1 FY27 Earnings Transcript: Revenue up 43% YoY, board approves INR200 cr capex
Order Pipeline DisclosedAnalyst Day Multiyear TargetsMgmt Guided Margin ImprovementInvestor Communications View source PDF
TATVA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.1%1-day move
₹1691.80
prior close
₹1700.00
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.6-2.6-2.5-2.7+1.1+1.6+7.5+2.4——————
Up moveDown movePending
AI summary
Q1 FY27 revenue up 43% YoY to INR1,671 million; EBITDA up 86% YoY at INR323 million. Board approved INR200 crore greenfield facility targeting about INR300 crore peak revenue. Management retained FY27 guidance of 25-30% revenue growth and 20-22% EBITDA margins. Three new pharma molecules expected to add INR70-80 crore this year, scaling to around INR200 crore. First semiconductor batch qualified by customer. Electrolyte Salts FY27 guidance maintained at INR40-60 crore.
Likely market impact
Strong growth across segments and new capex signal confidence. Multi-year visibility intact; near-term execution risk looks limited per management.